These blood biomarkers can predict drug efficacy or serious skin toxicity earlier than the occurrence of a skin rash, and it is more appropriate to predict the effect of EGFR inhibitors for patients who are not prone to skin toxicity. This evidence concerns the gene EGFR and dermatological toxicity.